Sorrento Therapeutics Stock Forecast, Price & News

Sorrento Therapeutics (NASDAQ:SRNE) Frequently Asked Questions

Is Sorrento Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sorrento Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sorrento Therapeutics stock.
View analyst ratings for Sorrento Therapeutics or view top-rated stocks.

How has Sorrento Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Sorrento Therapeutics' stock was trading at $1.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SRNE shares have increased by 221.1% and is now trading at $5.94.
View which stocks have been most impacted by COVID-19.

When is Sorrento Therapeutics' next earnings date?

Sorrento Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, February 18th 2022.
View our earnings forecast for Sorrento Therapeutics.

What price target have analysts set for SRNE?

3 brokerages have issued 1 year price objectives for Sorrento Therapeutics' stock. Their forecasts range from $25.00 to $35.00. On average, they expect Sorrento Therapeutics' stock price to reach $28.67 in the next year. This suggests a possible upside of 382.6% from the stock's current price.
View analysts' price targets for Sorrento Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Sorrento Therapeutics' key executives?

Sorrento Therapeutics' management team includes the following people:

• Henry H. Ji, Chairman, President & Chief Executive Officer
• Stephen L Klincewicz, VP-Pharmacovigilance & Clinical Operations
• Najjam Asghar, Chief Financial & Accounting Officer, SVP
• Mike A. Royal, Chief Medical Officer
• Alexis Nahama, Senior Vice President & Head-RTX Program

Who are some of Sorrento Therapeutics' key competitors?

Some companies that are related to Sorrento Therapeutics include CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Exelixis (EXEL), Beam Therapeutics (BEAM), Abcam (ABCM), Fate Therapeutics (FATE), Kodiak Sciences (KOD), Halozyme Therapeutics (HALO), Vir Biotechnology (VIR), Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Sana Biotechnology (SANA), SpringWorks Therapeutics (SWTX) and Relay Therapeutics (RLAY).
View all of SRNE's competitors.

What other stocks do shareholders of Sorrento Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sorrento Therapeutics investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Vaxart (VXRT), Advanced Micro Devices (AMD), Moderna (MRNA), NVIDIA (NVDA), ADMA Biologics (ADMA), Tesla (TSLA), Dynavax Technologies (DVAX) and NIO (NIO).

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

Who are Sorrento Therapeutics' major shareholders?

Sorrento Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.89%), Geode Capital Management LLC (1.65%), Bank of New York Mellon Corp (0.38%), Morgan Stanley (0.28%), Schroder Investment Management Group (0.23%) and Citadel Advisors LLC (0.00%). Company insiders that own Sorrento Therapeutics stock include Kim Janda and Robin L Smith.
View institutional ownership trends for Sorrento Therapeutics.

Which major investors are selling Sorrento Therapeutics stock?

SRNE stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Citadel Advisors LLC, Jane Street Group LLC, Schroder Investment Management Group, Emfo LLC, Credit Suisse AG, Morgan Stanley, and New York State Common Retirement Fund.
View insider buying and selling activity for Sorrento Therapeutics or view top insider-selling stocks.

Which major investors are buying Sorrento Therapeutics stock?

SRNE stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, UBS Group AG, State of New Jersey Common Pension Fund D, Bank of New York Mellon Corp, Rafferty Asset Management LLC, SG Americas Securities LLC, and Barclays PLC.
View insider buying and selling activity for Sorrento Therapeutics or or view top insider-buying stocks.

How do I buy shares of Sorrento Therapeutics?

Shares of SRNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sorrento Therapeutics' stock price today?

One share of SRNE stock can currently be purchased for approximately $5.94.

How much money does Sorrento Therapeutics make?

Sorrento Therapeutics has a market capitalization of $1.82 billion and generates $39.99 million in revenue each year. The biopharmaceutical company earns $-298.46 million in net income (profit) each year or ($1.23) on an earnings per share basis.

How many employees does Sorrento Therapeutics have?

Sorrento Therapeutics employs 502 workers across the globe.

What is Sorrento Therapeutics' official website?

The official website for Sorrento Therapeutics is www.sorrentotherapeutics.com.

Where are Sorrento Therapeutics' headquarters?

Sorrento Therapeutics is headquartered at 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121.

How can I contact Sorrento Therapeutics?

Sorrento Therapeutics' mailing address is 4955 DIRECTORS PLACE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at (858) 203-4100, via email at [email protected], or via fax at 858-210-3759.